MMTZFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as RLFTY

MindMaze Therapeutics Holding SA

Financials through fiscal 2023, year ended Dec 31, 2023Last filing: 20-F on Apr 30, 2024

$0.19−0.00 (-0.22%)

Close on Oct 19, 2026

MindMaze Therapeutics Holding SA income statement

AnnualQuarterlyTTM

CHF USD

Millions of CHF, except per-share data. Shares in millions.

Line item	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	6.33	7.11	4.49
Research & Development	1.33	12	19
General & Administrative	5.39	7.75	6.75
Operating Income	-111	-52	-34
Interest Expense	0.95	2.29	1.32
Interest & Investment Income	0.09	0.02	0.10
Pretax Income	-112	-54	-36
Income Tax Expense	-14	-3.53	-0.82
Net Income incl. Noncontrolling Interests	-98	-51	-35
EPS (Basic)(per share)	-8.35	-4.81	-4.00
EPS (Diluted)(per share)	-8.35	-4.81	-4.00
Shares Outstanding (Basic, Weighted)(shares)	12	11	8.98
Shares Outstanding (Diluted, Weighted)(shares)	12	11	8.98
EBITDA	-108	-48	-32

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2023

Profitability, FY2023

Gross margin: –
Operating margin: -1751.4%
Net margin: –
Return on equity, FY2023: –

Financial strength

Current ratio: 2.65
Debt to equity: –
Debt to assets: 0.5%
Cash to current liabilities: 210.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.